FDA/EMA Bioequivalence Collaboration Is Narrow In Scope, Wide In Reach
This article was originally published in The Pink Sheet Daily
Executive Summary
In contrast to the existing inspection program for clinical trials, sites around the globe will be targeted.
You may also be interested in...
Hamburg Says EMA Could Be Model For Global Regulatory Coalition
The FDA commissioner urges authorities to move away “from an outdated paradigm of only working in our own jurisdiction” in speech at European Medicines Agency’s 20th anniversary meeting.
Hamburg Says EMA Could Be Model For Global Regulatory Coalition
The FDA commissioner urges authorities to move away “from an outdated paradigm of only working in our own jurisdiction” in speech at European Medicines Agency’s 20th anniversary meeting.
FDA’s Hamburg Says EMA Could Be Model For Global Regulatory Coalition
Outgoing commissioner urges authorities to move away “from an outdated paradigm of only working in our own jurisdiction” in speech at European Medicines Agency’s 20th anniversary meeting.